BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 23990468)

  • 21. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Honokiol inhibits osteoclast differentiation and function in vitro.
    Hasegawa S; Yonezawa T; Ahn JY; Cha BY; Teruya T; Takami M; Yagasaki K; Nagai K; Woo JT
    Biol Pharm Bull; 2010; 33(3):487-92. PubMed ID: 20190414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
    Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
    J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages.
    Kim JL; Kang MK; Gong JH; Park SH; Han SY; Kang YH
    Mol Nutr Food Res; 2012 Aug; 56(8):1223-33. PubMed ID: 22700286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
    Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
    J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of two-pore channel 2 as a novel regulator of osteoclastogenesis.
    Notomi T; Ezura Y; Noda M
    J Biol Chem; 2012 Oct; 287(42):35057-35064. PubMed ID: 22833668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
    Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
    J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of ferric ion on the differentiation of osteoclast and bone resorption].
    Jia P; He YF; Gao C; Du HB; Hu ZY; Feng XQ; Li BY; Zhang ZL; Xu YJ; Lin H
    Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2214-8. PubMed ID: 23158430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.
    Ang ES; Pavlos NJ; Chai LY; Qi M; Cheng TS; Steer JH; Joyce DA; Zheng MH; Xu J
    J Cell Physiol; 2009 Dec; 221(3):642-9. PubMed ID: 19681045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effect of minocycline on osteoclastogenesis in mouse bone marrow cells.
    Nagasawa T; Arai M; Togari A
    Arch Oral Biol; 2011 Sep; 56(9):924-31. PubMed ID: 21377143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.
    Han SY; Kim YK
    Am J Chin Med; 2019; 47(2):439-455. PubMed ID: 30827151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.
    Shim KS; Ma CJ; Kim DS; Ma JY
    J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms involved in enhancement of osteoclast formation by activin-A.
    Kajita T; Ariyoshi W; Okinaga T; Mitsugi S; Tominaga K; Nishihara T
    J Cell Biochem; 2018 Aug; 119(8):6974-6985. PubMed ID: 29737562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species.
    Moon HJ; Kim SE; Yun YP; Hwang YS; Bang JB; Park JH; Kwon IK
    Exp Mol Med; 2011 Nov; 43(11):605-12. PubMed ID: 21832867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.